Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced that the company will be presenting new preclinical data on a monoclonal antibody to CXCR4 at the Cambridge Healthtech Institute's 13th Annual Molecular Medicine Tri- Conference, February 21st-24th at the Moscone North Convention Center in San Francisco, California.

CXCR4 is one of the most important cancer targets discovered in recent years, because it plays a central role in all three stages of cancer progression, and because it does so in over 75% of all cancers. Northwest Biotherapeutics will participate in the Preclinical Development poster session at the CHI conference on Wednesday, February 22nd and Thursday, February 23rd. Company President, Alton L. Boynton will be available to discuss the findings and the planned development of CXCR4 as a promising new cancer therapy target.

CXCR4 is over-expressed in more than 75% of cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. NWBT has previously completed and reported on several preclinical studies using monoclonal antibodies to block CXCR4 receptor function, and reported significant inhibition of cancer cell proliferation, motility and invasion in multiple preclinical models both in vitro and in vivo.

NWBT's study results are supported by a growing body of scientific literature confirming the key role of CXCR4 in all three major stages of cancer progression. Last month, researchers at the Vanderbilt-Ingram Cancer Center announced results from a preclinical study of CXCR4 in glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Reid Thompson, M.D., director of Neurosurgical Oncology, and his colleague, Moneeb Ehtesham, M.D., assistant professor of Neurological Surgery and Cancer Biology, were able to show a link between the expression of CXCR4 and the invasive behavior of brain tumor cells. This groundbreaking work supports NWBT's own data indicating that blocking the expression of CXCR4 could result in an effective treatment option for those suffering from a wide variety of cancers.

It is well documented and accepted that CXCR4 plays an important role in all three fundamental aspects of cancer: proliferation of the primary tumor, migration of tumor cells away from the primary tumor, and invasion and establishment of metastases at distant sites such as bone, lung and brain. "It is rare for a cancer-related protein to play an important role in all three functional stages of cancer cells, let alone to do so across many types of cancers," stated Dr. Alton Boynton. He continued, "CXCR4 offers an exceptional therapeutic opportunity to prevent proliferation of primary tumors and to prevent the metastatic spread of the disease."

In March 2005, Northwest Biotherapeutics announced that its United States patent had issued covering the broad use of CXCR4 antibodies for cancer therapeutics.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company's three lead product candidates are: DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and CXCR4 a therapeutic monoclonal antibody in late preclinical development for the treatment of cancer. For further information, please visit the company web site at

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in the planned Phase III trial of DCVax(R)-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax(R)-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Northwest Biotherapeutics, Inc.